Costanza Paoletti
Overview
Explore the profile of Costanza Paoletti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
956
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain E, et al.
Biomarkers
. 2023 Jan;
28(3):313-322.
PMID: 36647745
Background: Some patients with metastatic breast cancer (MBC) stay on endocrine therapy (ET) for years and others progress quickly. Serum thymidine kinase activity (TKa), an indicator of cell-proliferation, is a...
2.
Nanou A, Miao J, Coumans F, Dolce E, Darga E, Barlow W, et al.
JCO Precis Oncol
. 2023 Jan;
7():e2200372.
PMID: 36634296
Purpose: Circulating tumor cells (CTCs) are strongly prognostic for overall survival (OS) in metastatic breast cancer although additional prognostic biomarkers are needed. We evaluated the complementary prognostic value of tumor-derived...
3.
Cani A, Dolce E, Darga E, Hu K, Liu C, Pierce J, et al.
Mol Oncol
. 2021 Dec;
16(10):1969-1985.
PMID: 34866317
Nearly all estrogen receptor (ER)-positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of...
4.
Darga E, Dolce E, Fang F, Kidwell K, Gersch C, Kregel S, et al.
PLoS One
. 2021 Nov;
16(11):e0260124.
PMID: 34780566
Background: Immune checkpoint inhibition is effective in several cancers. Expression of programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could provide insights into selection of patients for...
5.
Paoletti C, Barlow W, Cobain E, Bergqvist M, Mehta R, Gralow J, et al.
Clin Cancer Res
. 2021 Sep;
27(22):6115-6123.
PMID: 34521624
Purpose: Serum thymidine kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC...
6.
Smith K, Jana J, Kaehr A, Purcell E, Opdycke T, Paoletti C, et al.
Lab Chip
. 2021 Jul;
21(18):3559-3572.
PMID: 34320046
Circulating tumor cells (CTCs) are extremely rare cells shed from tumors into the blood stream. These cells can provide valuable information about their tumor of origin and direct treatment decisions...
7.
Paoletti C, Regan M, Niman S, Dolce E, Darga E, Liu M, et al.
NPJ Breast Cancer
. 2021 Jun;
7(1):77.
PMID: 34117261
Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67...
8.
Kim T, Yoon H, Fouladdel S, Wang Y, Kozminsky M, Burness M, et al.
Adv Biosyst
. 2020 Jul;
3(2):e1800278.
PMID: 32627379
The enumeration of circulating tumor cells (CTCs) has shown prognostic importance in patients with breast cancer. However, CTCs are highly heterogeneous with diverse functional properties, which may also be clinically...
9.
Cobain E, Paoletti C, Smerage J, Hayes D
Recent Results Cancer Res
. 2019 Oct;
215:147-160.
PMID: 31605228
The development of metastatic disease accounts for the vast majority of cancer-related deaths in solid tumor malignancies. Distant metastases primarily develop as a result of tumor cell dissemination through the...
10.
Paoletti C, Miao J, Dolce E, Darga E, Repollet M, Doyle G, et al.
Clin Cancer Res
. 2019 Jul;
25(20):6089-6097.
PMID: 31358544
Purpose: Metastasis requires malignant cell circulation from the primary to a distant tissue. Elevated levels of circulating tumor cells (CTC) portend a poor prognosis in breast and other cancers. Recent...